Treatment with exenatide, a GLP-1 receptor agonist, was comparable to placebo in slowing the rate of Parkinson’s disease ...

The use of blockbuster weight loss drugs has surged among young women, for whom the treatments can often be "liberating." ...

The discovery and development of GLP-1 receptor agonists for type 2 diabetes and obesity is a bench-to-bedside success story.1 Multiple GLP-1 receptor agonists are now in clinical use, such as ...

Are you someone who is opting to buy fat jabs online? Then you might be in for a new surprise!Under new industry rules, ...

CagriSema combines semaglutide, the active ingredient in Wegovy, with a molecule that mimics a pancreatic hormone.

Discontinuation of GLP-1 receptor agonists in obesity is common, driven by weight regain and socioeconomic factors, impacting ...

The absolute risk for thyroid cancer is low among patients receiving GLP-1 RA therapy, but risk is elevated in the first year of treatment.

For people with diabetes, the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with a reduced risk for certain disorders and conditions.

Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...

The AP-NORC survey shows about half of U.S. adults believe it is a good thing for adults to use Ozempic, Wegovy and similar ...

LONDON/SAN FRANCISCO (Reuters) - Novo Nordisk is under pressure from investors for more information about its next-generation ...

Britain's pharmacies regulator on Tuesday tightened rules for online pharmacies' prescribing obesity drugs, ordering them to make changes to prevent people from receiving drugs that could cause them ...